𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increased urokinase activity to antigen ratio in human renal-cell carcinoma

✍ Scribed by Johannes C. Kirchheimer; Heinz Pflüger; Gregor Hienert; Bernd R. Binder

Publisher
John Wiley and Sons
Year
1985
Tongue
French
Weight
403 KB
Volume
35
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Eighteen patients with renal‐cell carcinoma have been investigated in an attempt to elucidate the ratio of active urokinase enzyme to urokinase antigen in the tumor and adjacent normal kidney. The tumor itself exhibited a significantly increased total fibrinolytic activity, an increase in the relative contribution of anti‐urokinase IgG‐inhibitable plasminogen activator activity and increased levels of urokinase antigen when compared to normal renal tissue. In tumor‐adjacent tissue total fibrinolytic activity was also, but not significantly, increased, this increase being completely due to tissue‐type plasminogen activator. Correlation of active urokinase‐type plasminogen activator with urokinase antigen revealed that in tumor tissue the enzyme was present to more than 70% in its active form whereas in tumor‐adjacent tissue and normal renal tissue only half of the enzyme appeared to be active. No correlation was obtained between urokinase antigen present in one of the 3 tissues investigated and plasma urokinase antigen.

📜 SIMILAR VOLUMES

TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR I
TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA
✍ WAGNER, STEPHAN N.; ATKINSON, MICHAEL J.; THANNER, STEPHANIE; SCHMITT, MANFRED; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 597 KB

In experimental models, plasminogen activator-mediated degradation of the extracellular matrix is inhibited by type-1 plasminogen activator inhibitor (PAI-1). PA14 has also been shown to protect tumour stromal tissue from autoproteolytic activities and may thus substantially promote tumour growth an

Clinical relevance of urokinase plasmino
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma
✍ Rainer Hofmann; Antonie Lehmer; Markus Buresch; Rudolf Hartung; Kurt Ulm 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

## BACKGROUND. Urokinase plasminogen activator (u-PA) plays a key role in the metastatic process by promoting plasmin mediated tissue degradation. Metastatic cell invasion requires localized proteolysis, which may be directed by u-PA receptor. The binding of u-PA and PAI-1 to the u-PA-receptor may

Renal cell carcinoma–associated antigen
Renal cell carcinoma–associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ T lymphocytes
✍ Joost L.M. Vissers; I. Jolanda M. de Vries; Linda P.H. Engelen; Nicole M. Schare 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 111 KB 👁 1 views

## Abstract We previously identified an HLA‐A2.1‐restricted epitope within the RCC‐associated antigen G250 that is recognized by CTLs. Using DCs of healthy individuals, which were loaded with overlapping 20 mer G250‐derived peptides, we here report the induction of CD4^+^ T cells that recognize the

Activation of the MN/CA9 gene is associa
Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines
✍ Masaki Cho; Karin Grabmaier; Yoshiteru Kitahori; Yoshio Hiasa; Yoshinori Nakagaw 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

The MN/CA9 (G250) gene expressed in the normal alimentary tract in a tissue-specific manner is often activated in renal cell carcinomas. To cast light on the activation mechanism, we examined the methylation status of this gene in seven human renal cell carcinoma cell lines and three normal kidney t

Retinoblastoma protein in human renal ce
Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins
✍ Ylva Hedberg; Börje Ljungberg; Göran Roos; Göran Landberg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 227 KB 👁 1 views

## Abstract The retinoblastoma gene product (pRb) is the main substrate for cyclin‐dependent kinases (CDKs) during the G1/S transition. Aberrations in cell cycle regulatory proteins, which have been observed in many malignancies, can theoretically cause increased phosphorylation of pRb due to unbal